{"id":390339,"date":"2019-10-25T00:00:00","date_gmt":"2019-10-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0006-2019-biopharma-psoriatic-arthritis-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-30T11:24:19","modified_gmt":"2026-04-30T11:24:19","slug":"dlsfim0006-2019-biopharma-psoriatic-arthritis-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0006-2019-biopharma-psoriatic-arthritis-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p><abbr title=\"psoriatic arthritis\">PsA<\/abbr>, a disease characterized\u00a0by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless,\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>\u00a0inhibitors have revolutionized treatment of the disease and expanded the\u00a0<abbr title=\"psoriatic arthritis\">PsA<\/abbr>\u00a0therapy market to a multibillion-dollar entity. In recent years, several novel therapies with alternative\u00a0<abbr title=\"mechanism of action\">MOA<\/abbr>s, such as the\u00a0<abbr title=\"interleukin\">IL<\/abbr>-12\/23 inhibitor ustekinumab, the oral\u00a0<abbr title=\"phosphodiesterase\">PDE<\/abbr>4 inhibitor apremilast, and the\u00a0<abbr title=\"interleukin\">IL<\/abbr>-17A inhibitor secukinumab, have entered this market and notably improved the outcome of patients who have an inadequate response to\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>\u00a0inhibitors.<\/p>\n<p>Three biologics and three oral agents are in late-phase development for\u00a0<abbr title=\"psoriatic arthritis\">PsA<\/abbr>\u00a0and are expected to launch during the 2018-2028\u00a0study period. Thought-leading physicians describe a dynamic patient-management environment with a growing need for additional novel therapies. In this content, we analyze physician perception and anticipated positioning of these agents and the implications for the market-leading\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>\u00a0inhibitor class.<\/p>\n","protected":false},"template":"","class_list":["post-390339","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriatic-arthritis","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390339\/revisions"}],"predecessor-version":[{"id":393464,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390339\/revisions\/393464"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}